目的 探討亮菌甲素聯(lián)合注射用頭孢唑林鈉治療慢性膽囊炎急性發(fā)作的臨床療效。方法 回顧性分析2020年6月—2022年12月在焦作市人民醫(yī)院治療的86例慢性膽囊炎急性發(fā)作患者臨床資料。根據(jù)用藥種類的不同分為對照組和治療組，每組各43例。對照組患者靜脈滴注注射用頭孢唑林鈉，2.0 g加入生理鹽水100 mL，1次/12 h；在此基礎(chǔ)上，治療組靜脈滴注注射用亮菌甲素，5.0 mg加入生理鹽水100 mL，1次/24 h。兩組患者均經(jīng)10 d治療。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時(shí)間，血清C反應(yīng)蛋白（CRP）、膽囊收縮素（CCK）、白細(xì)胞介素-6（IL-6）、核因子-κB（NF-κB）、腫瘤壞死因子-α（TNF-α）、天門冬酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）和總膽汁酸（TBA）水平。結(jié)果 治療后，治療組總有效率（97.96%）明顯高于對照組（83.67%，P＜0.05）。治療后，治療組右上腹疼痛、惡心嘔吐、口苦、腹脹改善時(shí)間上均早于對照組（P＜0.05）。治療后，兩組患者血清CRP、CCK、IL-6、NF-κB、TNF-α、AST、ALT和TBA水平均明顯下降（P＜0.05），且治療組這些血清學(xué)指標(biāo)明顯低于對照組（P＜0.05）。結(jié)論 亮菌甲素聯(lián)合注射用頭孢唑林鈉治療慢性膽囊炎急性發(fā)作可促進(jìn)臨床癥狀改善，降低肝損害，減輕機(jī)體炎癥反應(yīng)。

Objective Exploring the clinical efficacy of armillarisini anatricome combined with cefazolin sodium in treatment of acute exacerbation of chronic cholecystitis. Methods The clinical data of patients (86 cases) with acute exacerbation of chronic cholecystitis in Jiaozuo People’s Hospital from June 2020 to December 2022 were analyzed retrospectively. They were divided into control and treatment group, and each group had 43 cases based on different treatments. Patients in the control group were iv administered with Cefazolin Sodium for injection, 2 g added into normal saline 100 mL, once every 12 h. Patients in the treatment group were iv administered with Armillarisini Anatricome for injection on the basis of the control group, 5 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the levels of serum CRP, CCK, IL-6, NF-κB, TNF-α, AST, ALT, and TBA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.96%) was significantly higher than that of the control group (83.67%, P < 0.05). After treatment, the improvement time of right upper abdominal pain, nausea and vomiting, bitterness and abdominal distension in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the serum levels of CRP, CCK, IL-6, NF-κB, TNF-α, AST, ALT, and TBA were significantly decreased in two groups (P < 0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The combination of armillarisini anatricome and cefazolin sodium in treatment of acute exacerbation of chronic cholecystitis can promote the improvement of clinical symptoms, reduce liver damage and reduce inflammatory reaction.

R975